Back to investorsDR
View all positions →
Fund
Carlyle Group Inc.
Carlyle Group Inc.
AUM
$10B
Q2 2026
Filings
14
13F history
David Rubenstein’s latest 13F filing shows a portfolio built around special-situation bets, but the data is thin: no fund name, no AUM, and no top holdings were reported for the quarter. That absence is itself a signal. Rubenstein, a co-founder of one of the largest private equity firms, has long used his personal account to take concentrated, event-driven positions that do not fit a standard growth or value mandate. Without a disclosed holding list, the filing offers no fresh evidence of a new thesis, no shift in sector weight, and no clue about whether he is adding to a distressed energy name or trimming a legacy media stake.
What the filing does confirm is that Rubenstein’s public equity footprint remains a small, opportunistic sideline relative to his private market work. His style has historically favored special situations: spin-offs, restructuring plays, and companies with activist catalysts. Peers with similar backgrounds often run their personal 13Fs as a mirror of their firm’s strategy, but Rubenstein has diverged by keeping his public book lean and idiosyncratic. The lack of a fund name and AUM in the latest report suggests he is not managing third-party capital through this vehicle, which frees him from benchmark pressure and lets him hold positions for longer than a typical hedge fund.
The practical takeaway for readers is limited by the filing’s incompleteness. Rubenstein’s 13F is a trailing snapshot, and an empty top-holdings field means the most recent moves are invisible. Investors tracking him should wait for a subsequent filing that lists actual positions before drawing conclusions about his current conviction. Until then, the only defensible statement is that his public portfolio remains a minor, special-situation appendage to a much larger private investment operation.
AI-assisted summary
13F portfolio value
Disclosed portfolio value across 14 quarters of Carlyle Group Inc. filings.
Show data table
| Period | Portfolio value |
|---|---|
| Q1 2023 | $3.4B |
| Q2 2023 | $2.8B |
| Q3 2023 | $2.3B |
| Q4 2023 | $2.1B |
| Q1 2024 | $1.6B |
| Q2 2024 | $1.1B |
| Q3 2024 | $954.2M |
| Q4 2024 | $4.1B |
| Q1 2025 | $3.8B |
| Q2 2025 | $5B |
| Q3 2025 | $4.3B |
| Q4 2025 | $13.6B |
| Q1 2026 | $10.6B |
| Q2 2026 | $10B |
Current holdings
Top 15 positions as of Q2 2026, from Carlyle Group Inc.'s latest 13F.
| # | Stock | Value | Shares | % Portfolio | Change |
|---|---|---|---|---|---|
| 1 | $7.4B | 187.08M | 73.78% | Unchanged | |
| 2 | $2.5B | 84.59M | 25.30% | Unchanged | |
| 3 | $37.9M | 3.50M | 0.38% | Unchanged | |
| 4 | $20M | 662.9K | 0.20% | Trimmed(-0.2%) | |
| 5 | $16.4M | 2.36M | 0.16% | Unchanged | |
| 6 | $5.4M | 6.23M | 0.05% | Unchanged | |
| 7 | ? N/A Spruce Biosciences Inc | $2.1M | 38.6K | 0.02% | Unchanged |
| 8 | $1.6M | 2.34M | 0.02% | Added(+441.1%) | |
| 9 | $1.6M | 184.3K | 0.02% | Unchanged | |
| 10 | $1.4M | 107.2K | 0.01% | Unchanged | |
| 11 | $1.2M | 269.9K | 0.01% | Unchanged | |
| 12 | $1.2M | 340.7K | 0.01% | Unchanged | |
| 13 | $769K | 60.4K | 0.01% | Trimmed(-94.5%) | |
| 14 | $530K | 16.1K | 0.01% | — | |
| 15 | $510K | 1.8K | 0.01% | — |
Explore
Photo: Maryland GovPics · CC BY 2.0